"Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer

BACKGROUND: In a significant proportion of metastatic breast cancer (MBC) patients whose tumour has progressed within 6 months of endocrine therapy (de novo resistance), it is generally believed that the chance of achieving clinical benefit (CB) with further endocrine therapy is minimal. METHODS: Da...

Descripción completa

Detalles Bibliográficos
Autores principales: Agrawal, Amit, Robertson, John FR, Cheung, KL
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1538598/
https://www.ncbi.nlm.nih.gov/pubmed/16822312
http://dx.doi.org/10.1186/1477-7819-4-40

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1538598/
https://www.ncbi.nlm.nih.gov/pubmed/16822312
http://dx.doi.org/10.1186/1477-7819-4-40

Ejemplares similares